ERBB2 and breast carcinoma: To our knowledge, this is the first study to assess the cardiovascular impact of contemporary anti-neoplasmatic treatment in metastatic female breast cancer patients with HR-positive HER2-negative phenotype, using a combination of different techniques including PET-CT imaging.